In addition to isatuximab-mediated NK cell activation via engaging high-level CD38-expressing tumor cells, isatuximab treatment of purified NK cells also led to direct NK cell activation and release of IFN-γ and TNF-α in the absence of target cells. The gene discussed is IFNG; the disease is neoplasm.